SCHEMBL487288

SCHEMBL487288

C=C(C)c1cc(C(=O)Nc2ccc(CN3CCOCC3)cc2)c(OCc2ccccc2)cc1OCc1ccccc1

nearest known ligand 0.57

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 7/20 0.57
▸ RAB9A P51151 7/20 0.57
▸ SMN1; SMN2 Q16637 7/20 0.57
▸ TP53 P04637 2/20 0.57
▸ PTGER1 P34995 1/20 0.56
▸ HIF1A Q16665 2/20 0.53
▸ EPAS1 Q99814 2/20 0.53
▸ ALDH1A1 P00352 3/20 0.53
▸ HTT P42858 1/20 0.53
▸ CACNA1B Q00975 1/20 0.52
▸ APBA1 Q02410 1/20 0.52
▸ SAE1 Q9UBE0 1/20 0.52
▸ UBA2 Q9UBT2 1/20 0.52
▸ MAPT P10636 3/20 0.52
▸ KMT2A Q03164 1/20 0.51
▸ L3MBTL1 Q9Y468 2/20 0.51
▸ MAPK1 P28482 2/20 0.50
▸ LMNA P02545 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20509703 0.86 SMN1; SMN2 (0.56) NPC1RAB9ASMN1; SMN2TP53PTGER1
SCHEMBL30779603 0.86 SMN1; SMN2 (0.56) NPC1RAB9ASMN1; SMN2TP53PTGER1
SCHEMBL487594 0.86 NPC1 (0.52) NPC1RAB9ASMN1; SMN2TP53PTGER1
SCHEMBL487607 0.83 HIF1A (0.48) NPC1RAB9ASMN1; SMN2PTGER1HIF1A
SCHEMBL14029848 0.82 PTGER1 (0.55) NPC1RAB9ASMN1; SMN2TP53PTGER1
SCHEMBL487587 0.81 PDK1 (0.49) SMN1; SMN2PTGER1HIF1AMAPTKMT2A
SCHEMBL488035 0.80 SGMS2 (0.57) NPC1RAB9ASMN1; SMN2PTGER1ALDH1A1
SCHEMBL21644610 0.79 KDM1A (0.50) NPC1RAB9ASMN1; SMN2TP53PTGER1
SCHEMBL30779631 0.79 KDM1A (0.50) NPC1RAB9ASMN1; SMN2TP53PTGER1
SCHEMBL17740268 0.79 HIF1A (0.65) NPC1RAB9ASMN1; SMN2TP53PTGER1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8106057-B2 Dihydroxyphenyl isoindolylmethanones ASTEX THERAPEUTICS, LTD. (GB) 2012-01-31 — — US disclosed
US-20100286167-A1 DIHYDROXYPHENYL ISOINDOLYLMETHANONES ASTEX THERAPEUTICS LTD. (GB) 2010-11-11 — — US disclosed
US-7754725-B2 Dihydroxyphenyl isoindolymethanones ASTEX THERAPEUTICS LTD. (GB) 2010-07-13 — — US disclosed
US-20080306054-A1 Pharmaceutical Compounds ASTEX THERAPEUTICS LIMITED (GB) 2008-12-11 — — US disclosed
EP-1883402-A2 HYDROXYBENZAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF HSP90 Astex Therapeutics Limited (GB) 2008-02-06 — — EP disclosed
US-20070259886-A1 (2,4-Dihydroxy-5-isopropyl-phenyl)-[5-(2-dimethylamino-ethoxy)-1,3-dihydro-isoindol-2-yl]-methanone; inhibits or modulates activity of heat shock protein Hsp90; useful for treating cancer, particularly hematopoietic tumors of lymphoid or myeloid lineage, prostate, lung, breast cancer, melanoma ASTEX THERAPEUTICS, LTD. (GB) 2007-11-08 — — US disclosed
WO-2006109075-A2 HYDROXYBENZAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF HSP90 ASTEX THERAPEUTICS LIMITED (GB) 2006-10-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100286167-A1 DIHYDROXYPHENYL ISOINDOLYLMETHANONES HSP90AA1, HSP90AB1, HSP90AB2P NPC1 2964/4885RAB9A 2935/4885SMN1; SMN2 4130/4885
US-20070259886-A1 (2,4-Dihydroxy-5-isopropyl-phenyl)-[5-(2-dimethylamino-ethoxy)-1,3-dihydro-isoindol-2-yl]-methanone; inhibits or modulates activity of heat shock protein Hsp90; useful for treating cancer, particularly hematopoietic tumors of lymphoid or myeloid lineage, prostate, lung, breast cancer, melanoma HSP90AB2P, HSP90AA1, HSP90AB1 NPC1 3796/4885RAB9A 3474/4885SMN1; SMN2 4290/4885
US-20080306054-A1 Pharmaceutical Compounds HSP90AB1, HSP90AA1, HSP90AB2P NPC1 439/4885RAB9A 2852/4885SMN1; SMN2 4554/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback